Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$5.25 +7.0%	$4.40	$1.58 ▼ $7.27	$468.08M	-0.6	1.21 million shs	482,500 shs
ARVN Arvinas	$7.21 -3.8%	$7.34	$5.90 ▼ $34.34	$526.48M	2.21	1.36 million shs	1.24 million shs
VTYX Ventyx Biosciences	$1.70 -6.4%	$1.24	$0.78 ▼ $5.66	$120.62M	0.73	1.34 million shs	772,651 shs
ZVRA Zevra Therapeutics	$8.53 -1.0%	$7.63	$4.20 ▼ $9.76	$466.75M	1.87	644,564 shs	170,791 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+2.30%	-8.58%	0.00%	+49.39%	+193.41%
ARVN Arvinas	+3.02%	+15.92%	-19.96%	-57.63%	-77.88%
VTYX Ventyx Biosciences	+2.26%	-0.55%	+41.41%	+14.56%	-63.29%
ZVRA Zevra Therapeutics	+3.48%	+0.58%	+19.23%	+7.62%	+87.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.9305 of 5 stars	4.6	1.0	3.2	4.2	1.3
ARVN Arvinas	3.6179 of 5 stars	4.3	2.0	3.1	2.5	1.3
VTYX Ventyx Biosciences	3.1416 of 5 stars	3.4	3.0	4.1	2.5	0.6
ZVRA Zevra Therapeutics	2.8477 of 5 stars	4.6	0.0	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.11	Buy	$9.83	87.48% Upside
ARVN Arvinas	2.60	Moderate Buy	$20.92	190.03% Upside
VTYX Ventyx Biosciences	2.75	Moderate Buy	$10.00	489.97% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	161.14% Upside

Current Analyst Ratings Breakdown

Latest VTYX, ARVN, AMLX, and ZVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/9/2025	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/5/2025	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.50
5/5/2025	ARVN Arvinas	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $10.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-367.57	$0.95 per share	5.51	$6.42 per share	0.82
ARVN Arvinas	$426.90M	1.23	N/A	N/A	$8.17 per share	0.88
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$4.13 per share	N/A
ZVRA Zevra Therapeutics	$40.59M	11.50	N/A	N/A	$1.71 per share	4.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$3.11	N/A	N/A	N/A	N/A	-36.97%	-29.61%	8/14/2025 (Estimated)
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-75.51%	-33.75%	-16.75%	7/29/2025 (Estimated)
VTYX Ventyx Biosciences	-$192.96M	-$1.75	N/A	N/A	N/A	N/A	-54.94%	-50.01%	8/14/2025 (Estimated)
ZVRA Zevra Therapeutics	-$46.05M	-$1.90	N/A	42.67	N/A	-342.63%	-159.54%	-51.50%	8/12/2025 (Estimated)

Latest VTYX, ARVN, AMLX, and ZVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/8/2025	Q1 2025	VTYX Ventyx Biosciences	-$0.48	-$0.39	+$0.09	-$0.39	N/A	N/A
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A
3/11/2025	Q4 2024	ZVRA Zevra Therapeutics	-$0.39	-$0.67	-$0.28	-$0.67	$8.93 million	$12.00 million
3/4/2025	Q4 2024	AMLX Amylyx Pharmaceuticals	-$0.49	-$0.55	-$0.06	-$0.55	N/A	($0.67) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	19.37%	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
ARVN Arvinas	N/A	4.64	4.64
VTYX Ventyx Biosciences	N/A	23.52	23.52
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ARVN Arvinas	95.19%
VTYX Ventyx Biosciences	97.88%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
ARVN Arvinas	4.73%
VTYX Ventyx Biosciences	14.49%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	60.53 million	Optionable
ARVN Arvinas	420	72.99 million	65.18 million	Optionable
VTYX Ventyx Biosciences	30	71.16 million	57.86 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

VTYX, ARVN, AMLX, and ZVRA Headlines

Recent News About These Companies

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29 at 4:35 PM | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27 at 1:28 PM | insidermonkey.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by Analysts

May 27 at 1:16 AM | marketbeat.com

Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 25, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street Zen

May 24, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen

May 24, 2025 | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LP

May 23, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

May 21, 2025 | marketbeat.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

May 20, 2025 | marketbeat.com

Roth Capital Lifts Earnings Estimates for Zevra Therapeutics

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 14, 2025 | taiwannews.com.tw

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Wednesday

May 9, 2025 | marketbeat.com

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025 | globenewswire.com

Barclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, ARVN, AMLX, and ZVRA Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$5.24 +0.35 (+7.04%)

As of 03:03 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Arvinas NASDAQ:ARVN

$7.21 -0.29 (-3.84%)

As of 03:04 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Ventyx Biosciences NASDAQ:VTYX

$1.70 -0.12 (-6.35%)

As of 03:03 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Zevra Therapeutics NASDAQ:ZVRA

$8.53 -0.09 (-1.00%)

As of 03:03 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time